This was a recent post on DrugResearcher.com, by Mike Nagle, which demonstrates further that big pharmaceutical companies are beginning to deeper integrate themselves with China.
GlaxoSmithKline (GSK) is the latest pharma heavyweight to set up a drug research centre in China.
Jingwu Zang has been appointed to run the new R&D facility in Shanghai, effective as of June. The centre will focus on creating new drugs for neurodegenerative disorders, such as multiple sclerosis, Parkinson's disease and Alzheimer's disease.
Several companies are looking to exploit the growth of China within the pharma industry. Over the next three years, China is predicted to become the joint fifth largest pharma market, alongside the UK with an estimated value of $24bn (€18bn), according to data from the Boston Consulting Group.
This trend was further highlighted just last week, when DrugResearcher.com reported that three Shanghai-based contract research organisations (CROs) have teamed up to form an R&D alliance.
GSK hopes the new centre will eventually direct global research within its therapeutic area, with the company refocusing its "largely UK-based neurology drug discovery efforts on finding new therapies for pain, epilepsy and brain injury", according to GSK's head of R&D, Dr Moncef Slaoui.
To view the entire article at its original location click on the title of this post.
AdMark China is committed to finding for our clients the best possible talent as quickly as possible. Contact us at email@example.com or at +86 21 6288 9292.